Cardiovascular · Medical DevicesSafety Signalcommercialnear-term

Abiomed recalls 14Fr Low Profile Introducer Kits due to thrombus risk

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/18/2026, 12:32:03 PM

Assessment confidence: 56% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The recall of Abiomed's introducer kits due to thrombus risk raises significant safety concerns that could affect market dynamics. Portfolio and strategy teams must evaluate the potential impact on Abiomed's sales and the competitive landscape as similar devices may come under scrutiny. Regulatory context from FDA (Catheter Introducer Kit Recall: Abiomed Removes 14Fr Low Profile Introducer Kits) supports the near-term read. Assessment grounded in 26 ranked evidence items (6 high-relevance).

Strategic Assessment

Portfolio and strategy teams should assess the impact of this recall on Abiomed's sales and consider potential shifts in market share among competitors. The strongest clinical anchor is Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using Low Specific Absorption Rate (SAR) Scanner System (ClinicalTrials.gov), mechanism alignment (io ). In Cardiovascular · Medical Devices, 7 regulatory and 5 competitive items passed relevance filtering for Abiomed.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). Secondary pressure from B. Braun Medical Recalls Spinal Anesthesia Kits Due to Bupivacaine Hydrochloride Issues. This recall may impact Abiomed's market position and raise concerns about the safety of similar devices from competitors.

Regulatory Outlook

Regulatory risk is concentrated around Catheter Introducer Kit Recall: Abiomed Removes 14Fr Low Profile Introducer Kits (FDA). Entity match (abiomed). Relevant agencies in corpus: FDA, MHRA. The recall indicates potential compliance issues that may prompt increased scrutiny from regulatory bodies, affecting future approvals and market access for similar devices.

Key Risks

Elevated medium regulatory exposure for Abiomed could delay market entry or constrain labeling if agency review intensifies.
Signal severity is high — leadership review is warranted.
Regulatory risk from FDA (Early Alert: Catheter Introducer Issue from Abiomed and Oscor) could weigh on Abiomed through agency review timelines and labeling constraints if follow-through weakens.
Regulatory risk from FDA (Heart Pump Correction: Abiomed Issues Correction for Automated Impella Controllers) could weigh on Abiomed through agency review timelines and labeling constraints if follow-through weakens.
Regulatory risk from FDA (NARA ORGANICS RECALLS ALL LOTS OF NARA INFANT FORMULA BECAUSE OF POSSIBLE HEALTH RISK) could weigh on Abiomed through agency review timelines and labeling constraints if follow-through weakens.

Key Opportunities

This recall could lead to a decline in Abiomed's market share, while competitors may experience shifts in sales as healthcare providers reassess their device options.
Fayus Inc., doing business as Yusol International Foods (Sacramento, CA) is voluntarily recalling OLA-OLA POUNDED YAM because the product may contain undeclared milk in the form of sodium caseinate, which is not declared on the label.
Upside for Abiomed may improve if Benefit-risk profile comparison between dupilumab and upadacitinib: a structured benefit-risk assessment of the Heads Up trial. (PubMed) delivers favorable follow-through.
CDK4/6 inhibitors (CDK4/6i) represent the standard treatment for HR+/HER2- ABC. The study assessed the efficacy and safety profiles of CDK4/6i from first-line (1 L) to third-line (3 L) in patients with HR+/HER2- ABC from high-altitude versus low-altitude regions.
Anesthesia · Injectable · Safety Signal · This recall may impact B. Braun's market position in the anesthesia segment, potentially benefiting competitors with safer alternatives.

What Would Change This Assessment

This becomes more urgent if Monitor for further safety communications from Abiomed and competitor responses to the recall.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Catheter Introducer Kit Recall: Abiomed Removes 14Fr Low Profile Introducer Kits
FDAhigh relevance
Entity match (abiomed)
FDA document
View source
Early Alert: Catheter Introducer Issue from Abiomed and Oscor
FDAhigh relevance
Entity match (abiomed)
FDA document
View source
Heart Pump Correction: Abiomed Issues Correction for Automated Impella Controllers
FDAhigh relevance
Entity match (abiomed)
FDA document
View source
Faysu Inc., dba Yusol International Foods Recalls OLA-OLA POUNDED YAM Due to Undeclared Milk Allergen
FDAhigh relevance
Regulatory pathway relevance (label)
FDA document
View source
NARA ORGANICS RECALLS ALL LOTS OF NARA INFANT FORMULA BECAUSE OF POSSIBLE HEALTH RISK
FDAmedium relevance
Regulatory pathway relevance (nda)
FDA document
View source
Fayus Inc., dba Yusol International Foods Recalls OLA-OLA POUNDED YAM Due to Undeclared Milk Allergen
FDAmedium relevance
Regulatory pathway relevance (label)
FDA document
View source
Botulinum toxin type A products: updated warnings regarding risk of iatrogenic botulism
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source

Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using Low Specific Absorption Rate (SAR) Scanner System
ClinicalTrials.govhigh relevance
Mechanism alignment (IO )
FDA document
View source
Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Effectiveness of Coordinated Care to Reduce the Prolonged Disability Risk Among Patients Suffering From Low Back Pain in Primary Care
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Effect of Dry Needling Plus Vibration on Myofascial Trigger Points in Individuals With Nonspecific Low Back Pain
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Medical Adhesive and Barrier Products for Preventing MARSI in Central Venous Catheter Dressings
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
B. Braun Medical Recalls Spinal Anesthesia Kits Due to Bupivacaine Hydrochloride Issues
Humanexa Signalsmedium relevance
Moderate corpus alignment
Updated Warnings on Botulinum Toxin Type A Products Due to Iatrogenic Botulism Risk
Humanexa Signalsmedium relevance
Moderate corpus alignment
Baxter Issues Correction for Volera Positive Pressure Breathing Devices Due to Air Leakage
Humanexa Signalsmedium relevance
Moderate corpus alignment
Resmed Astral Ventilators Face Serious Electrical Component Failure Risk
Humanexa Signalsmedium relevance
Moderate corpus alignment

A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13).
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Lactiplantibacillus plantarum (WJL) ameliorates chronic kidney disease by inhibiting fibroblast growth factor 21 adaptive stress response via low protein diet.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Safety and efficacy of ashwagen (a standardized withania somnifera extract) in stress and anxiety with hypertension and associated cardiometabolic risk factors: a randomized, placebo-controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Benefit-risk profile comparison between dupilumab and upadacitinib: a structured benefit-risk assessment of the Heads Up trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Low-intensity pulsed ultrasound combined with microbubbles enhances amphotericin B delivery across the blood-brain barrier for improved therapy of cryptococcal meningitis.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Increasing plant protein sources in the diet modulates gut microbiota and tryptophan metabolism in men at cardiometabolic risk.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Abiomed
competitors in cardiovascular devices

Commercial impact

medium

This recall could lead to a decline in Abiomed's market share, while competitors may experience shifts in sales as healthcare providers reassess their device options.

Regulatory impact

medium

The recall indicates potential compliance issues that may prompt increased scrutiny from regulatory bodies, affecting future approvals and market access for similar devices.

What to watch

Monitor for further safety communications from Abiomed and competitor responses to the recall.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.